Richard T. Maziarz - Concepedia

Author

Richard T. Maziarz

Oregon Health & Science University ORCID

Also Known As

Alyn, Irene B., Carreras, Jeanette, Carrie Kitko, Hofmeister, Craig C., Maziarz, Richard T., Parsons, Susan K., Popat, Uday, R Maziarz, R T Maziarz, R. Maziarz

725

Publications

32.1K

Citations

H-Index

174

Concepts

All Affiliations

Oregon Health & Science University Fred Hutch Cancer Center Medical College of Wisconsin The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Richard T. Maziarz is an author at Oregon Health & Science University specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	102	7K
2	Health Sciences	26	39	3.8K
3	Engineering	1	1	33
4	Natural Sciences	1	1	93
5	Nursing	1	1	53

Richard T. Maziarz

270

Publications

30.2K

Citations

H-Index

Page 1

	Year	Citations
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster, Michael Bishop, Constantine S. Tam, New England Journal of Medicine	2018	3.9K
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, New England Journal of Medicine	2012	1.1K
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation Philippe Armand, Haesook T. Kim, Brent R. Logan, Blood	2014	916
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors Claudio Anasetti, Brent R. Logan, Stephanie J. Lee, New England Journal of Medicine	2012	882
Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients Hillard M. Lazarus, Omer N. Koç, Steven M. Devine, Biology of Blood and Marrow Transplantation	2005	792
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, Blood	2009	773
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff, Journal of Clinical Oncology	2009	670
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaImmunologyOptimal Regimen IntensityMyeloid NeoplasiaHematological Malignancy	2017	649
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineLong-term Clinical OutcomesImmunology	2021	528
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma Michael R. Bishop, Michael Dickinson, Duncan Purtill, New England Journal of Medicine	2021	491

Page 1